TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update

Conference Call and Live Audio Webcast Scheduled for Today, April 5, 2018, at 4:30 p.m. ET

[/vc_column_text][vc_column_text]Recent Corporate and Clinical Developments:

  • Published long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200
  • Commenced dosing in 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC
  • Enhanced IP portfolio for PolyStart™ technology, expanding to cover any polypeptide sequences comprising poly-antigen arrays (PAAs)
  • Appointed Dr. Richard Kenney as Acting Chief Medical Officer

Upcoming Anticipated Milestones:

  • Q3 2018: Report interim immune response data from ongoing Phase 2 TNBC
  • 2H 2018: Report interim results from ongoing Phase 2 study of TPIV200 in combination with AstraZeneca’s durvalumab in patients with platinum-resistant ovarian cancer
  • 2018: Mayo Clinic to initiate Phase 1b/2a study of TPIV100 in women with HER2/neu+ ductal carcinoma in situ (DCIS) breast cancer
  • 1Q 2019: Report interim safety and futility results from Phase 2 ovarian cancer study

JACKSONVILLE, FLORIDA – April 5, 2018 – TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today provided its business update for the fourth quarter and year-end 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.

“Throughout 2017, we made significant advances toward achieving our goals and reaching our milestones,” said Peter Hoang, President and CEO of TapImmune. “We recently announced the publication of new clinical data for our multi-epitope T-cell vaccine targeting folate receptor alpha, TPIV200, in patients with ovarian and breast cancer.  In this publication we showed an encouraging potential progression-free survival benefit in women with ovarian cancer in their first remission, which we are currently exploring further in an ongoing randomized Phase 2 study.  Should we see a similar, prolonged PFS in this larger study, we believe that TPIV200 could have a viable pathway toward potential approval in this indication, for which it has FDA Fast Track designation.  We remain on track to conduct an interim safety and futility analysis for the Phase 2 study by mid-2019.”

Mr. Hoang continued, “With multiple Phase 2 and Phase 1/2 clinical studies ongoing, several of which are funded by U.S. Department of Defense grants, and our preclinical PolyStart™ technology maturing rapidly to the point where it may drive value through strategic partnership, we believe TapImmune is on a strong growth trajectory that will continue through 2018 and beyond.  Our progress will be measured by continued milestone execution and we look forward to building value at each step along the way.”

Current Clinical Studies:

TPIV200: Lead T-cell vaccine targeting folate receptor alpha

  • FDA Fast-tracked Phase 2 maintenance therapy study in platinum-sensitive ovarian cancer

TapImmune is currently enrolling women who have completed initial therapy with a platinum regimen and are in first remission. Enrollment remains on track with projections and the company plans to conduct a blinded interim safety and futility analysis once the data from the first half of enrollment is achieved and responses mature, which is currently expected by mid-2019.  This program benefits from FDA Fast Track and Orphan Drug designation.

  • Multi-center Phase 2 dosing study in triple-negative breast cancer

The randomized study is designed to determine the optimal vaccine dose and regimen that may maximize the anti-tumor immune response in maintenance-phase patients who have completed standard surgery and chemotherapy/radiation. Enrollment in this study is complete and TapImmune expects to report interim immune response data in the third quarter 2018.

  • U.S. Department of Defense (DoD)-funded Phase 2 efficacy study in advanced triple-negative breast cancer

In late 2017, the Mayo Clinic successfully dosed the first patient in a Phase 2 study designed to evaluate the safety and efficacy of TPIV200 in prolonging disease-free survival in women with advanced triple-negative breast cancer. This 280-patient randomized, double-blind and placebo-controlled study is completely funded by a $13.3 million grant from the U.S. DoD.

  • Memorial Sloan Kettering-sponsored Phase 2 combination study with AstraZeneca’s durvalumab in platinum-resistant ovarian cancer

Data from the first 27 patients enrolled in the study are currently being analyzed by the study’s clinical investigators at MSKCC.  TapImmune anticipates reporting the results based on these 27 patients once patient analysis at MSKCC is released.

Planned Clinical Studies:

TPIV100/110 T-cell vaccine targeting HER2/neu:

  • Mayo Clinic is expected to initiate a Phase 1b/2a study of TPIV100 in women with an early form of breast cancer called ductal carcinoma in situ (DCIS).  This study is also fully funded by a grant from the U.S. DoD. If successful, TapImmune’s HER2/neu-targeted vaccine may complement standard surgery and chemotherapy.
  • TapImmune planned to submit FDA filings for its five-peptide HER2 vaccine, TPIV110, and begin a Phase 1/2 clinical study in women with HER2-low breast cancer. In the fourth quarter, the U.S. DoD expressed interest in fully funding a larger Phase 2 clinical study using TPIV110 in combination with Herceptin® (trastuzumab) in HER2neu+ breast cancer.  TapImmune is currently engaged in discussions with the Mayo Clinic and the U.S. DoD regarding this Phase 2 study, which would supplant the previously planned TapImmune-sponsored Phase 1/2 study. TapImmune will provide an update once the details of the study and the required FDA filings are finalized.

Conference Call and Webcast Information:

To access the live conference call on April 5, 2018, at 4:30pm ET you may use:

  • (855) 238-2333 (U.S.)
  • (412) 317-5215 (International)

To access the live audio webcast, visit the Events section of the TapImmune website https://www.markertherapeutics.com/events. The webcast will also be archived for 90 days beginning at approximately 6:30 p.m. ET, on April 5, 2018.[/vc_column_text][vc_empty_space height=”4px”][vc_column_text][pr-disclaimer][/vc_column_text][vc_empty_space height=”4px”][vc_column_text]



December 31, 2017 December 31, 2016
Current assets:
     Cash $5,129,289 $7,851,243
     Prepaid expenses and deposits 51,150 70,149
          Total current assets 5,180,439 7,921,392
Total assets $5,180,439 $7,921,392
Current liabilities:
     Accounts payable and accrued liabilities $1,508,312 $1,224,940
     Research agreement obligations 492,365
     Warrant liability 9,000 14,500
     Promissory note 5,000 5,000
          Total current liabilities 1,522,312 1,736,805
Total liabilities 1,522,312 1,736,805
Stockholders’ equity:
Preferred stock – $0.001 par value, 5 million shares authorized at December 31, 2017 and 2016, respectively
     Series A, $0.001 par value, 1.25 million shares designated, 0

shares issued and outstanding as of December 31, 2017 and

2016, respectively

     Series B, $0.001 par value, 1.5 million shares designated, 0

shares issued and outstanding as of December 31, 2017 and

2016, respectively

     Common stock, $0.001 par value, 41.7 million shares

authorized, 10.6 million and 8.4 million shares issued and

outstanding as of December 31, 2017 and 2016, respectively

10,616 8,421
     Additional paid-in capital 161,067,538 151,991,974
     Accumulated deficit  (157,420,027)  (145,815,808)
Total stockholders’ equity 3,658,127 6,184,587
Total liabilities and stockholders’ equity $5,180,439 $7,921,392




For the Years Ended
December 31, 2017 December 31, 2016
     Research and development $5,250,985 $3,800,035
     General and administrative 6,412,121 4,692,234
Total operating expenses 11,663,106 8,492,269
Loss from operations  (11,663,106)  (8,492,269)
     Change in fair value of warrant liabilities 5,500 5,939,500
     Debt extinguishment gain 492,365
     Grant income 183,064 231,200
     Loss on debt settlement agreements  (135,640)
     Other income 1,828
NET LOSS $(10,982,177) $(2,455,381)
Basic net loss per share $(1.16) $(0.36)
Diluted net loss per share $(1.16) $(0.72)
Weighted average number of common shares outstanding, basic 9,453,483 6,889,898
Weighted average number of common shares outstanding, diluted 9,453,483 7,420,995




For the Years Ended
December 31, 2017 December 31, 2016
Net loss $(10,982,177) $(2,455,381)
Reconciliation of net loss to net cash used in operating activities:
     Changes in fair value of warrant liabilities  (5,500)  (5,939,500)
     Shares issued in debt settlement agreements 70,315
     Stock-based compensation 2,738,244 1,558,409
     Debt extinguishment gain  (492,365)
     Changes in operating assets and liabilities:
          Prepaid expenses and deposits 18,999  (1,346)
          Accounts payable and accrued expenses 283,372 257,582
               Net cash used in operating activities  (8,439,427)  (6,509,921)
Proceeds from issuance of common stock and warrants in private placement, net of offering costs 5,408,343 2,331,126
Proceeds from exercise of stock warrants, net of offering costs 619,623 5,483,349
Proceeds from exercise of stock options 18,125
Repayment of promissory note  (25,000)
Repayment of promissory note – related party  (23,000)
Repurchase of common stock to pay for employee withholding taxes  (310,493)
     Net cash provided by financing activities 5,717,473 7,784,600
Net (decrease) increase in cash  (2,721,954) 1,274,679
Cash at beginning of period 7,851,243 6,576,564
CASH AT END OF PERIOD $5,129,289 $7,851,243